144 related articles for article (PubMed ID: 12895697)
1. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
Antiviral Res; 2003 Jul; 59(2):137-42. PubMed ID: 12895697
[TBL] [Abstract][Full Text] [Related]
2. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
Izumi K; Kawaji K; Miyamoto F; Shimane K; Shimura K; Sakagami Y; Hattori T; Watanabe K; Oishi S; Fujii N; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
Int J Biochem Cell Biol; 2013 Apr; 45(4):908-15. PubMed ID: 23357451
[TBL] [Abstract][Full Text] [Related]
4. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
Bean P
Am Clin Lab; 2002 Oct; 21(8):15-6. PubMed ID: 12440170
[No Abstract] [Full Text] [Related]
5. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
Jiang S; Debnath AK
Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
[TBL] [Abstract][Full Text] [Related]
6. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
7. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
Lohrengel S; Hermann F; Hagmann I; Oberwinkler H; Scrivano L; Hoffmann C; von Laer D; Dittmar MT
J Virol; 2005 Aug; 79(16):10237-46. PubMed ID: 16051817
[TBL] [Abstract][Full Text] [Related]
8. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
9. Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.
Wang W; De Feo CJ; Zhuang M; Vassell R; Weiss CD
J Virol; 2011 Dec; 85(24):12929-38. PubMed ID: 21994458
[TBL] [Abstract][Full Text] [Related]
10. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
11. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.
Kliger Y; Gallo SA; Peisajovich SG; Munoz-Barroso I; Avkin S; Blumenthal R; Shai Y
J Biol Chem; 2001 Jan; 276(2):1391-7. PubMed ID: 11027678
[TBL] [Abstract][Full Text] [Related]
12. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
13. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
Rimsky LT; Shugars DC; Matthews TJ
J Virol; 1998 Feb; 72(2):986-93. PubMed ID: 9444991
[TBL] [Abstract][Full Text] [Related]
14. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
[TBL] [Abstract][Full Text] [Related]
15. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
Armand-Ugón M; Clotet-Codina I; Tintori C; Manetti F; Clotet B; Botta M; Esté JA
Virology; 2005 Dec; 343(1):141-9. PubMed ID: 16168454
[TBL] [Abstract][Full Text] [Related]
16. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
17. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
19. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
20. Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.
Chinnadurai R; Münch J; Kirchhoff F
AIDS; 2005 Sep; 19(13):1401-5. PubMed ID: 16103771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
